CAMBRIDGE, Mass., February 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team ...
TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...
TD Cowen was established in 1918 as a bond trading firm and quickly expanded into clearing and execution services. By the 1970s, it had carved a niche in railroad bonds and grown a solid research ...
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for ...
TD Cowen initiated coverage of Centessa (CNTA) with a Buy rating and no price target The firm says the company’s ORX750 has a “best in class profile as a transformative therapy” in excessive ...
The data center backtrack is the latest sign of shakiness from a major tech company after China’s DeepSeek spooked the ...
The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment ...
TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback